About Convergence Pharma
Convergence Pharma is a company based in Babraham (United Kingdom) founded in 2010 was acquired by Biogen in January 2015. Convergence Pharma has raised $35.4 million across 1 funding round from investors including Biogen, New Leaf Venture Partners and Apposite Capital. Convergence Pharma operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
- Headquarter Babraham, United Kingdom
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Old Convergence Pharmaceuticals Limited
- Date of Incorporation 18 Jun, 2010
- Jurisdiction MAIDENHEAD, BERKSHIRE, ENGLAND
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Convergence Pharma
Convergence Pharma has successfully raised a total of $35.4M through 1 strategic funding round. The most recent funding activity was a Series A round of $35.4 million completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Convergence Pharma
Convergence Pharma has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, New Leaf Venture Partners and Apposite Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked | |
|
Healthcare impact investments are managed by Apposite Capital.
|
Locked | Locked | Locked | |
|
Venture capital fund focused on early-stage healthcare startups
|
Locked | Locked | Locked |
Investor details for Convergence Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Convergence Pharma
Investment portfolio details for Convergence Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Convergence Pharma
Detailed financials for Convergence Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Convergence Pharma Comparisons
Peer comparison for Convergence Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Convergence Pharma
Convergence Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for pain management are developed with abuse-deterrent designs.
|
Detailed competitors of Convergence Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Convergence Pharma
Complete news archive for Convergence Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Convergence Pharma
Convergence Pharma was founded in 2010.
Convergence Pharma is headquartered in Babraham, United Kingdom. It is registered at Babraham, Cambridgeshire, United Kingdom.
Convergence Pharma is a funded company, having raised a total of $35.4M across 1 funding round to date.
Convergence Pharmaceuticals was formed in 2010 after neuroscience clinical assets were acquired from GlaxoSmithKline. Focus is placed on biotechnology for novel analgesics targeting chronic pain through ion-channel modulation, including a pipeline of clinical-stage compounds for voltage-gated sodium channels. Operations are conducted from Babraham, United Kingdom, in the analgesics sector. The company was acquired by Biogen in February 2015.
Convergence Pharma's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.
Convergence Pharma has 4 investors. Key investors include Biogen, New Leaf Venture Partners, Apposite Capital, and SV Health Investors.